nexobrid
Generic: anacaulase-bcdb·Brand: Nexobrid
nexobrid: developed by 2 companies · 1 FDA decision.
nexobrid evidence translation
What we can confirm
1 FDA record
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about nexobrid, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Removal of eschar in adult and pediatric patients with deep partial-thickness and/or full-thickness thermal burns
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| MediWound Ltd. (MDWD) | Approved |
| Vericel Corp (VCEL) Removal of eschar in adult and pediatric patients with deep … | Approved |
FDA Decisions1 records
Frequently asked questions
Who is developing nexobrid?
nexobrid is being developed by MediWound Ltd., Vericel Corp.
What is nexobrid's latest FDA decision?
The most recent tracked FDA decision for nexobrid is Approval, dated December 28, 2022.